1. Home
  2. MTA vs MGTX Comparison

MTA vs MGTX Comparison

Compare MTA & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Metalla Royalty & Streaming Ltd.

MTA

Metalla Royalty & Streaming Ltd.

SELL

Current Price

$7.79

Market Cap

902.2M

Sector

N/A

ML Signal

SELL

Logo MeiraGTx Holdings plc

MGTX

MeiraGTx Holdings plc

HOLD

Current Price

$9.40

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTA
MGTX
Founded
1983
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
902.2M
1.0B
IPO Year
2017
2018

Fundamental Metrics

Financial Performance
Metric
MTA
MGTX
Price
$7.79
$9.40
Analyst Decision
Buy
Buy
Analyst Count
2
8
Target Price
$9.16
★ $27.75
AVG Volume (30 Days)
286.9K
★ 1.0M
Earning Date
08-13-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 33.02
EPS
N/A
★ 1.30
Revenue
N/A
★ $81,391,000.00
Revenue This Year
$68.62
$314.19
Revenue Next Year
$67.46
N/A
P/E Ratio
★ N/A
$7.24
Revenue Growth
N/A
★ 144.57
52 Week Low
$5.95
$6.62
52 Week High
$11.60
$15.35

Technical Indicators

Market Signals
Indicator
MTA
MGTX
Relative Strength Index (RSI) 27.13 23.75
Support Level $6.34 $8.84
Resistance Level $7.97 $10.06
Average True Range (ATR) 0.31 0.50
MACD -0.17 -0.09
Stochastic Oscillator 3.54 3.29

Price Performance

Historical Comparison
MTA
MGTX

About MTA Metalla Royalty & Streaming Ltd.

Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company that engages in the acquisition and management of precious metal and copper royalties and streams. It generates revenue from royalties, streams, and other interests. Geographically, the company generates revenue from Australia, Brazil, Mexico, and the USA.

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.

Share on Social Networks: